OTCMKTS:SNYNF

Sanofi (SNYNF) Stock Price, News & Analysis

$94.00
-0.25 (-0.27%)
(As of 04/24/2024 ET)
Today's Range
$94.00
$95.00
50-Day Range
$92.12
$99.96
52-Week Range
$86.12
$114.90
Volume
310 shs
Average Volume
32,541 shs
Market Capitalization
N/A
P/E Ratio
30.47
Dividend Yield
2.98%
Price Target
N/A

Sanofi MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.26
Upright™ Environmental Score
News Sentiment
0.09mentions of Sanofi in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.49 out of 5 stars

SNYNF stock logo

About Sanofi Stock (OTCMKTS:SNYNF)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNYNF Stock Price History

SNYNF Stock News Headlines

Sanofi Q1 Profit Drops, Sales Rise; Confirms FY24 Outlook
Sanofi Pharma Ltd.
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
Sanofi: My Top Pick In Big Pharma
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
Sanofi SA SAN Stock Quote
See More Headlines
Receive SNYNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:SNYNF
Fax
N/A
Employees
86,088
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul Hudson (Age 57)
    CEO & Director
    Comp: $4M
  • Mr. François-Xavier Roger (Age 62)
    Executive VP & CFO
  • Ms. Madeleine Roach (Age 40)
    Executive VP & Head of Business Operations
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and Vice President of Corporate Accounting
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 46)
    Executive VP & General Counsel
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 67)
    Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

SNYNF Stock Analysis - Frequently Asked Questions

How have SNYNF shares performed in 2024?

Sanofi's stock was trading at $99.61 at the beginning of 2024. Since then, SNYNF shares have decreased by 5.6% and is now trading at $94.00.
View the best growth stocks for 2024 here
.

Is Sanofi a good dividend stock?

Sanofi (OTCMKTS:SNYNF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 4.13%. SNYNF has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 90.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

How do I buy shares of Sanofi?

Shares of SNYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SNYNF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners